LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist B in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset (ID:20359)
Download: Excel (XLSX), Comma-separated (CSV)
| Small Molecule | barcode | cell_count | frac_dead | corpse_count | cell_count_dead | row | column | agent | concentration | role | timepoint | replicate | cell_line | dead_count | fraction_dead | cell_count__time0 | dead_count__time0 | cell_count__ctrl | dead_count__ctrl | fraction_dead__ctrl | increase_fraction_dead | GRvalue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Etoposide | 180614_BG_02 | 16700 | 0.0207 | 47 | 299 | 4 | 7 | Etoposide | 0.003326667 | treatment | 72 | 1 | MCF10A-GM_1 | 346 | 0.0203 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.00030 | 0.9902 |
| Etoposide | 180614_BG_02 | 1041 | 0.1240 | 72 | 66 | 3 | 4 | Etoposide | 3.193598006 | treatment | 72 | 1 | MCF10A-GM_1 | 138 | 0.1170 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.09705 | 0.0377 |
| Dasatinib | 180614_BG_02 | 9659 | 0.0255 | 27 | 220 | 5 | 17 | Dasatinib | 0.099799999 | treatment | 72 | 1 | MCF10A-GM_1 | 247 | 0.0249 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.00494 | 0.7502 |
| Dasatinib | 180614_BG_02 | 684 | 0.6242 | 77 | 398 | 4 | 13 | Dasatinib | 9.98 | treatment | 72 | 1 | MCF10A-GM_1 | 475 | 0.4098 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.38984 | -0.0596 |
| Etoposide | 180614_BG_02 | 9985 | 0.0235 | 68 | 168 | 7 | 4 | Etoposide | 0.099799999 | treatment | 72 | 1 | MCF10A-GM_1 | 236 | 0.0231 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.00309 | 0.7639 |
| Etoposide | 180614_BG_02 | 1135 | 0.0935 | 52 | 59 | 3 | 6 | Etoposide | 0.997999808 | treatment | 72 | 1 | MCF10A-GM_1 | 111 | 0.0891 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.06909 | 0.0590 |
| Dasatinib | 180614_BG_02 | 17431 | 0.0166 | 32 | 258 | 9 | 14 | Dasatinib | 0.00998 | treatment | 72 | 1 | MCF10A-GM_1 | 290 | 0.0164 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | -0.00363 | 1.0103 |
| Alpelisib | 180614_BG_02 | 13929 | 0.0157 | 24 | 195 | 5 | 20 | Alpelisib | 0.316033316 | treatment | 72 | 1 | MCF10A-GM_1 | 219 | 0.0155 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | -0.00452 | 0.9072 |
| Dasatinib | 180614_BG_02 | 3912 | 0.0740 | 21 | 270 | 3 | 22 | Dasatinib | 0.997999808 | treatment | 72 | 1 | MCF10A-GM_1 | 291 | 0.0692 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.04924 | 0.4158 |
| Dasatinib | 180614_BG_02 | 1183 | 0.2795 | 37 | 304 | 7 | 20 | Dasatinib | 3.193598006 | treatment | 72 | 1 | MCF10A-GM_1 | 341 | 0.2238 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.20376 | 0.0693 |
| Etoposide | 180614_BG_02 | 17281 | 0.0194 | 48 | 289 | 9 | 5 | Etoposide | 0.00998 | treatment | 72 | 1 | MCF10A-GM_1 | 337 | 0.0191 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | -0.00087 | 1.0062 |
| Etoposide | 180614_BG_02 | 14860 | 0.0170 | 41 | 212 | 9 | 12 | Etoposide | 0.033266667 | treatment | 72 | 1 | MCF10A-GM_1 | 253 | 0.0167 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | -0.00325 | 0.9364 |
| Dasatinib | 180614_BG_02 | 13937 | 0.0147 | 40 | 166 | 8 | 21 | Dasatinib | 0.033266667 | treatment | 72 | 1 | MCF10A-GM_1 | 206 | 0.0146 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | -0.00543 | 0.9075 |
| Etoposide | 180614_BG_02 | 3662 | 0.0464 | 66 | 107 | 8 | 4 | Etoposide | 0.316033316 | treatment | 72 | 1 | MCF10A-GM_1 | 173 | 0.0451 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.02512 | 0.3940 |
| Alpelisib | 180614_BG_02 | 17542 | 0.0211 | 36 | 335 | 7 | 14 | Alpelisib | 0.003326667 | treatment | 72 | 1 | MCF10A-GM_1 | 371 | 0.0207 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.00072 | 1.0133 |
| Alpelisib | 180614_BG_02 | 15804 | 0.0194 | 71 | 237 | 3 | 7 | Alpelisib | 0.099799999 | treatment | 72 | 1 | MCF10A-GM_1 | 308 | 0.0191 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | -0.00088 | 0.9646 |
| Alpelisib | 180614_BG_02 | 12302 | 0.0143 | 23 | 153 | 5 | 3 | Alpelisib | 0.997999808 | treatment | 72 | 1 | MCF10A-GM_1 | 176 | 0.0141 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | -0.00589 | 0.8524 |
| Alpelisib | 180614_BG_02 | 16925 | 0.0228 | 77 | 311 | 13 | 4 | Alpelisib | 0.033266667 | treatment | 72 | 1 | MCF10A-GM_1 | 388 | 0.0224 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.00242 | 0.9964 |
| Alpelisib | 180614_BG_02 | 16563 | 0.0198 | 43 | 285 | 3 | 12 | Alpelisib | 0.00998 | treatment | 72 | 1 | MCF10A-GM_1 | 328 | 0.0194 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | -0.00058 | 0.9863 |
| Dasatinib | 180614_BG_02 | 5506 | 0.0406 | 42 | 183 | 8 | 14 | Dasatinib | 0.316033316 | treatment | 72 | 1 | MCF10A-GM_1 | 225 | 0.0393 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.01926 | 0.5340 |
| Dasatinib | 180614_BG_02 | 17360 | 0.0204 | 53 | 303 | 3 | 3 | Dasatinib | 0.003326667 | treatment | 72 | 1 | MCF10A-GM_1 | 356 | 0.0201 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.00010 | 1.0084 |
| Alpelisib | 180614_BG_02 | 9366 | 0.0236 | 56 | 166 | 6 | 13 | Alpelisib | 3.193598006 | treatment | 72 | 1 | MCF10A-GM_1 | 222 | 0.0232 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.00316 | 0.7376 |
| Alpelisib | 180614_BG_02 | 5374 | 0.0236 | 46 | 82 | 8 | 17 | Alpelisib | 9.98 | treatment | 72 | 1 | MCF10A-GM_1 | 128 | 0.0233 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.00327 | 0.5253 |
| Neratinib | 180614_BG_02 | 16786 | 0.0176 | 52 | 245 | 3 | 13 | Neratinib | 0.001081167 | treatment | 72 | 1 | MCF10A-GM_1 | 297 | 0.0174 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | -0.00261 | 0.9926 |
| Etoposide | 180614_BG_02 | 1013 | 0.0862 | 54 | 38 | 4 | 15 | Etoposide | 9.98 | treatment | 72 | 1 | MCF10A-GM_1 | 92 | 0.0833 | 889.0 | 105.5 | 17054 | 348.0 | 0.0200 | 0.06326 | 0.0311 |